8r67

Publication Abstract from PubMed

Cryptophycins are microtubule-targeting agents (MTAs) that belong to the most potent antimitotic compounds known to date; however, their exact molecular mechanism of action remains unclear. Here, we present the 2.2 A resolution X-ray crystal structure of a potent cryptophycin derivative bound to the alphabeta-tubulin heterodimer. The structure addresses conformational issues present in a previous 3.3 A resolution cryo-electron microscopy structure of cryptophycin-52 bound to the maytansine site of beta-tubulin. It further provides atomic details on interactions of cryptophycins, which had not been described previously, including ones that are in line with structure-activity relationship (SAR) studies. Interestingly, we discovered a second cryptophycin-binding site that involves the T5-loop of beta-tubulin, a critical secondary structure element involved in the exchange of the guanosine nucleotide and in the formation of longitudinal tubulin contacts in microtubules. Cryptophycins are the first natural ligands found to bind to this new "betaT5-loop site" that bridges the maytansine and vinca sites. Our results offer unique avenues to rationally design novel MTAs with the capacity to modulate T5-loop dynamics and to simultaneously engage multiple beta-tubulin binding sites.

Bridging the maytansine and vinca sites: cryptophycins target beta-tubulin's T5-loop.,Abel AC, Muhlethaler T, Dessin C, Schachtsiek T, Sammet B, Sharpe T, Steinmetz MO, Sewald N, Prota AE J Biol Chem. 2024 May 10:107363. doi: 10.1016/j.jbc.2024.107363. PMID:38735475^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.